AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
Novel Agents and Strategies in Lung Cancer
Oncology Today with Dr Neil Love
Tarlatumab Approval: Insights from the Delphi 301 Study
This chapter covers the recent approval of Tarlatumab, a bispecific T cell engager, focusing on its clinical trial results from the Delphi 301 study. With a reported response rate of 40% and critical metrics like duration of response and median overall survival, the chapter also examines the dosing strategies and comparisons within the trial.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode